Longevity’s goal is to give people agency over the number of healthy years they live. It's just medicine without the incorrect assumption that there is a physical upper bound on the number of years a sentient being can live. The first Longevity Fund was closed in 2013. Since then, we backed some of the first longevity companies to IPO and get plausible drug candidates to market. In 2018, we started an accelerator to test the hypothesis that founder-driven companies in longevity would be critical to build the moonshots in the field. That experiment did well, and we’ve branded our subsequent fund age1 to reflect this focus.